Intelligent bio solutions announces fiscal q3 2025 financial results and key operational achievements

20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended march 31, 2025  35 new accounts and international growth during q3 bring total active accounts to over 450 new york, may 13, 2025 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) (“inbs” or the “company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended march 31, 2025, and provided a business update.   the company delivered a strong quarter of growth in revenue compared to the previous quarter, supported by ongoing expansion across safety-critical industries and steady customer acquisition.
INBS Ratings Summary
INBS Quant Ranking